NCT02449239View on ClinicalTrials.gov

Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG

PHASE3CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2022

Conditions
Bladder Cancer
Interventions
BIOLOGICAL

Vicinium

Intravesical administration

Trial Locations (70)

10032

New York

10461

The Bronx

12208

Albany

12601

Poughkeepsie

13210

Syracuse

15232

Pittsburgh

19004

Bala-Cynwyd

19010

Bryn Mawr

20010

Washington D.C.

21061

Glen Burnie

22908

Charlottesville

23235

Richmond

28025

Concord

29401

Charleston

29425

Charleston

30322

Atlanta

32114

Daytona Beach

32803

Orlando

33449

Wellington

33612

Tampa

33710

St. Petersburg

34205

Bradenton

35294

Birmingham

44130

Middleburg Heights

47130

Jeffersonville

48109

Ann Arbor

60010

Lake Barrington

66205

Fairway

66214

Lenexa

67208

Wichita

68130

Houston

70112

New Orleans

72211

Little Rock

73014

Oklahoma City

75231

Dallas

76508

Temple

77030

Houston

79920

El Paso

80113

Englewood

83642

Meridian

83814

Coeur d'Alene

85032

Phoenix

85741

Tucson

87109

Albuquerque

90017

Los Angeles

90048

Los Angeles

90089

Los Angeles

90095

Los Angeles

90505

Torrance

91411

Sherman Oaks

92404

San Bernardino

94062

Redwood City

96813

Honolulu

97239

Portland

02111

Boston

01805

Burlington

01655

Worcester

03756

Lebanon

08724

Brick

08648

Lawrenceville

07960

Morristown

B3H 2Y9

Halifax

L4M 7G1

Barrie

L6H 3P1

Oakville

M4N 3M5

Toronto

M5G 2C4

Toronto

H2X 0A4

Montreal

H4A 3J1

Montreal

H9R 4S3

Pointe-Claire

J1E 3Z6

Sherbrooke

All Listed Sponsors
lead

Sesen Bio, Inc.

INDUSTRY

NCT02449239 - Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG | Biotech Hunter | Biotech Hunter